<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556761</url>
  </required_header>
  <id_info>
    <org_study_id>829444</org_study_id>
    <nct_id>NCT03556761</nct_id>
  </id_info>
  <brief_title>Furosemide for Accelerated Recovery of Blood Pressure Postpartum</brief_title>
  <acronym>ForBP</acronym>
  <official_title>Furosemide for Accelerated Recovery of Blood Pressure Postpartum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled single center investigation of furosemide's&#xD;
      effect on postpartum blood pressure control in pregnancies affected by hypertensive disorders&#xD;
      of pregnancy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertensive disorders of pregnancy are recognized causes of significant maternal/fetal&#xD;
      morbidity and mortality, accounting for approximately 18% of maternal deaths worldwide. While&#xD;
      significant research has been done on the evaluation and management of hypertension during&#xD;
      pregnancy, studies of postpartum hypertension (PPHTN) are usually limited by their&#xD;
      retrospective design and focus on inpatients in the immediate postpartum period (2-6 days),&#xD;
      or patients who were readmitted due to complications related to hypertension. Few studies&#xD;
      have investigated the incidence and proper management of hypertension in the postpartum&#xD;
      period. Furthermore, in the United Kingdom, a review of maternal deaths determined that 10%&#xD;
      were related to hypertensive disorders in pregnancy (HDP) in the postpartum period.&#xD;
      Postpartum hypertension is also the cause of approximately 27% of readmissions to the&#xD;
      hospital. These studies clearly show that PPHTN is associated with significant morbidity and&#xD;
      that it is important to develop interventions that can reduce its effects.&#xD;
&#xD;
      In patients with HDP, postpartum blood pressure has been shown to decrease in the first 48&#xD;
      hours postpartum only to then increase in days 3-6 postpartum. This phenomenon is thought to&#xD;
      be secondary to large fluid shifts, both secondary from fluid retention during the pregnant&#xD;
      state as well as from fluids given intrapartum. Furthermore, large volumes of sodium are also&#xD;
      mobilized into the intravascular compartment at this time. Given the latter, furosemide, a&#xD;
      loop diuretic that mobilizes sodium and fluid excretion has been posed as a method to prevent&#xD;
      severe range blood pressures and their associated maternal morbidity in the postpartum&#xD;
      period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2018</start_date>
  <completion_date type="Actual">February 5, 2020</completion_date>
  <primary_completion_date type="Actual">December 4, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind, randomized, placebo control design</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study medication (furosemide) and placebo will be stored at room temperature at the University of Pennsylvania research pharmacy. Pharmacy will be responsible for labeling and randomizing the medications.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Persistently Elevated Blood Pressures 7 Days Postpartum</measure>
    <time_frame>0-7 days postpartum</time_frame>
    <description>To compare the rate of persistently elevated blood pressures (&gt;140/90) in women that receive a five day furosemide course compared to those that receive placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Resolution</measure>
    <time_frame>0-14 days postpartum</time_frame>
    <description>To compare the time (days) required to achieve a resolution of elevated blood pressure, adjusted for mode of delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postpartum Readmission</measure>
    <time_frame>0-6 weeks postpartum</time_frame>
    <description>Number of subjects with one or more readmission/ER visit that were hypertension related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Had Severe Hypertension Postpartum</measure>
    <time_frame>0-6 weeks postpartum</time_frame>
    <description>Number of women who had severe hypertension (systolic blood pressure&gt;160 millimeters of mercury or diastolic blood pressure&gt;110 millimeters of mercury) postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum Length of Stay</measure>
    <time_frame>0-6 weeks postpartum</time_frame>
    <description>Number of days postpartum participants stayed in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Complications During Hospitalization</measure>
    <time_frame>0-6 weeks postpartum</time_frame>
    <description>Subjects with complications during hospitalization related to hypertensive disorders of pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing One or More Adverse Effects</measure>
    <time_frame>0-6 weeks postpartum</time_frame>
    <description>Number of subjects experiencing one or more adverse effects secondary to furosemide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects That Required for Additional Antihypertensives</measure>
    <time_frame>0 to 6 weeks post-partum</time_frame>
    <description>Number of subjects that required additional hypertensive medication after discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">384</enrollment>
  <condition>Hypertension, Pregnancy-Induced</condition>
  <arm_group>
    <arm_group_label>Oral furosemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once per day for a total of 5 consecutive doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral furosemide</intervention_name>
    <description>Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
    <arm_group_label>Oral furosemide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo, PO, daily</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hypertensive disorder of pregnancy diagnosed antepartum or intrapartum&#xD;
&#xD;
          -  Gestational hypertension&#xD;
&#xD;
          -  Pre-eclampsia with or without severe features&#xD;
&#xD;
          -  Superimposed pre-eclampsia with or without severe features&#xD;
&#xD;
          -  New diagnosis of HDP within 24 hours from delivery&#xD;
&#xD;
          -  Postpartum, delivery ≥ 20 weeks estimated gestational age&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergic reaction to furosemide&#xD;
&#xD;
          -  High risk comorbidities for which treatment may be indicated or contraindicated: class&#xD;
             C or higher diabetes mellitus, chronic kidney disease or baseline creatinine &gt;1.2,&#xD;
             cardiac disorders including cardiomyopathy, congenital heart disease, angina or&#xD;
             coronary heart disease, rheumatic disease (lupus), sickle cell disease&#xD;
&#xD;
          -  Baseline labs with K &lt;3&#xD;
&#xD;
          -  Use of furosemide or other diuretics antepartum or intrapartum&#xD;
&#xD;
          -  Use of ototoxic agents including aminoglycosides (ie, Gentamicin for &gt;1 dose),&#xD;
             cephalosporins (ie Ancef &gt;1 dose),&#xD;
&#xD;
          -  Patient unstable for protocol per investigator's judgement&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <results_first_submitted>August 2, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2020</results_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Lisa Levine</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Furosemide</keyword>
  <keyword>Postpartum</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03556761/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03556761/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Furosemide</title>
          <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.&#xD;
Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo Oral Tablet</title>
          <description>Placebo once per day for a total of 5 consecutive doses.&#xD;
Placebo Oral Tablet: Placebo, PO, daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="192"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Furosemide</title>
          <description>Oral tablet of furosemide 20 mg once daily for a total of 5 consecutive doses.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Oral Tablet</title>
          <description>Oral tablet of placebo once daily for a total of 5 consecutive doses.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="192"/>
            <count group_id="B2" value="192"/>
            <count group_id="B3" value="384"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="22" upper_limit="32"/>
                    <measurement group_id="B2" value="27" lower_limit="23" upper_limit="33"/>
                    <measurement group_id="B3" value="27" lower_limit="22" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="384"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertensive Disorders of Pregnancy (HDP)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Non-severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at delivery</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" lower_limit="37.3" upper_limit="39.7"/>
                    <measurement group_id="B2" value="38.4" lower_limit="37.3" upper_limit="39.7"/>
                    <measurement group_id="B3" value="38.5" lower_limit="37.3" upper_limit="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cesarean delivery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Persistently Elevated Blood Pressures 7 Days Postpartum</title>
        <description>To compare the rate of persistently elevated blood pressures (&gt;140/90) in women that receive a five day furosemide course compared to those that receive placebo.</description>
        <time_frame>0-7 days postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Furosemide</title>
            <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.&#xD;
Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>Placebo once per day for a total of 5 consecutive doses.&#xD;
Placebo Oral Tablet: Placebo, PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Persistently Elevated Blood Pressures 7 Days Postpartum</title>
          <description>To compare the rate of persistently elevated blood pressures (&gt;140/90) in women that receive a five day furosemide course compared to those that receive placebo.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Regression, Linear</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Resolution</title>
        <description>To compare the time (days) required to achieve a resolution of elevated blood pressure, adjusted for mode of delivery.</description>
        <time_frame>0-14 days postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Furosemide</title>
            <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.&#xD;
Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>Placebo once per day for a total of 5 consecutive doses.&#xD;
Placebo Oral Tablet: Placebo, PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution</title>
          <description>To compare the time (days) required to achieve a resolution of elevated blood pressure, adjusted for mode of delivery.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="6.25" upper_limit="12.5"/>
                    <measurement group_id="O2" value="10.5" lower_limit="6.5" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postpartum Readmission</title>
        <description>Number of subjects with one or more readmission/ER visit that were hypertension related</description>
        <time_frame>0-6 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Furosemide</title>
            <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.&#xD;
Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>Placebo once per day for a total of 5 consecutive doses.&#xD;
Placebo Oral Tablet: Placebo, PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Postpartum Readmission</title>
          <description>Number of subjects with one or more readmission/ER visit that were hypertension related</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Had Severe Hypertension Postpartum</title>
        <description>Number of women who had severe hypertension (systolic blood pressure&gt;160 millimeters of mercury or diastolic blood pressure&gt;110 millimeters of mercury) postpartum</description>
        <time_frame>0-6 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Furosemide</title>
            <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.&#xD;
Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>Placebo once per day for a total of 5 consecutive doses.&#xD;
Placebo Oral Tablet: Placebo, PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Had Severe Hypertension Postpartum</title>
          <description>Number of women who had severe hypertension (systolic blood pressure&gt;160 millimeters of mercury or diastolic blood pressure&gt;110 millimeters of mercury) postpartum</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postpartum Length of Stay</title>
        <description>Number of days postpartum participants stayed in the hospital</description>
        <time_frame>0-6 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Furosemide</title>
            <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.&#xD;
Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>Placebo once per day for a total of 5 consecutive doses.&#xD;
Placebo Oral Tablet: Placebo, PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Postpartum Length of Stay</title>
          <description>Number of days postpartum participants stayed in the hospital</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="2" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Regression, Linear</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Complications During Hospitalization</title>
        <description>Subjects with complications during hospitalization related to hypertensive disorders of pregnancy.</description>
        <time_frame>0-6 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Furosemide</title>
            <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.&#xD;
Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>Placebo once per day for a total of 5 consecutive doses.&#xD;
Placebo Oral Tablet: Placebo, PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Complications During Hospitalization</title>
          <description>Subjects with complications during hospitalization related to hypertensive disorders of pregnancy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing One or More Adverse Effects</title>
        <description>Number of subjects experiencing one or more adverse effects secondary to furosemide</description>
        <time_frame>0-6 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Furosemide</title>
            <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.&#xD;
Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>Placebo once per day for a total of 5 consecutive doses.&#xD;
Placebo Oral Tablet: Placebo, PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing One or More Adverse Effects</title>
          <description>Number of subjects experiencing one or more adverse effects secondary to furosemide</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>28.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects That Required for Additional Antihypertensives</title>
        <description>Number of subjects that required additional hypertensive medication after discharge</description>
        <time_frame>0 to 6 weeks post-partum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Furosemide</title>
            <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.&#xD;
Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>Placebo once per day for a total of 5 consecutive doses.&#xD;
Placebo Oral Tablet: Placebo, PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Required for Additional Antihypertensives</title>
          <description>Number of subjects that required additional hypertensive medication after discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 6 weeks postpartum</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Furosemide</title>
          <description>Oral furosemide 20 mg/day for a total of 5 consecutive doses.&#xD;
Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo Oral Tablet</title>
          <description>Placebo once per day for a total of 5 consecutive doses.&#xD;
Placebo Oral Tablet: Placebo, PO, daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <description>Pulmonary edema</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Lisa Levine</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-662-6913</phone>
      <email>lisa.levine@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

